Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor

Movement Disorders : Official Journal of the Movement Disorder Society
Adrian Handforth, Fredricka C Martin

Abstract

The purpose of this pilot single-site study was to assess efficacy and safety of levetiracetam for essential tremor, using a placebo-controlled, double-blind, randomized crossover design with an interim analysis planned after completion of the first 10 to 15 subjects. The study was designed to detect a mean 30% reduction in composite tremor score, comparable to that of primidone or propranolol, which can be demonstrated with 30 or fewer subjects. Each treatment arm included baseline tremor assessments, a 4-week medication titration, 2 weeks of stable dose, and treatment tremor assessments. Levetiracetam was titrated to 3,000 mg/day or to a lower maximal tolerated dose. The median age was 72 years, with 28 years median tremor duration. There was no statistically significant difference in response between placebo and levetiracetam on any tremor rating scale or accelerometry measure. The 95% confidence interval for the true mean difference between placebo and levetiracetam treatments was +18.5 to -22.5%, which excludes the minimum 30% drop required to consider levetiracetam clinically effective to a degree comparable to primidone or propranolol. Whether levetiracetam has lesser-degree antitremor efficacy was not addressed in this ...Continue Reading

References

Apr 1, 1989·Clinical Neuropharmacology·W C Koller
Jul 1, 1986·Acta Neurologica Scandinavica·H TeräväinenT A Larsen
Jan 1, 1986·Journal of Neurology, Neurosurgery, and Psychiatry·W P GormanM J Campbell
Dec 1, 1984·Controlled Clinical Trials·T R FlemingP C O'Brien
May 1, 1996·Movement Disorders : Official Journal of the Movement Disorder Society·J JankovicJ Mordaunt
Dec 1, 1996·Clinical Neuropharmacology·J DuarteL E Clavería
Apr 23, 1997·European Journal of Pharmacology·G J SillsM J Brodie
Sep 3, 1998·European Journal of Pharmacology·H KlitgaardE Wülfert
Aug 6, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·W OndoJ Jankovic
Sep 16, 2000·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·D G Margineanu, H Klitgaard
Jul 24, 2001·Seizure : the Journal of the British Epilepsy Association·C ZonaD G Margineanu
Sep 12, 2001·Neurology·Y H SohnM Hallett
Mar 7, 2002·Epilepsia·E A LukyanetzP G Kostyuk
Mar 29, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Robert SchauerMarkus Kofler

❮ Previous
Next ❯

Citations

Jul 25, 2013·Current Treatment Options in Neurology·Theresa A ZesiewiczKelly L Sullivan
Oct 4, 2006·Nature Reviews. Drug Discovery·Anthony H V SchapiraGiora Davidai
Dec 20, 2007·Clinical Neuropharmacology·Rodger J ElbleRajesh Pahwa
Sep 15, 2010·Clinical Neuropharmacology·Adrian HandforthArnulfo Quesada
Feb 10, 2012·Clinical Neuropharmacology·Mihály HercegNorbert Kovács
Oct 22, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Susanne A Schneider, Günther Deuschl
Sep 13, 2015·Seizure : the Journal of the British Epilepsy Association·Alberto VerrottiGaetano Zaccara
Jun 30, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Steven J FruchtDayton Reardan
Jan 2, 2009·Movement Disorders : Official Journal of the Movement Disorder Society·Adrian HandforthZeba Vanek
May 4, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Kitty K WongPeter A Kempster
Nov 22, 2005·Lancet Neurology·John C Morgan, Kapil D Sethi
Jan 21, 2016·Journal of Clinical Movement Disorders·Pichet Termsarasab, Steven J Frucht
Mar 30, 2005·Expert Opinion on Pharmacotherapy·Courtney R SchadtP David Charles
Jun 9, 2016·Movement Disorders : Official Journal of the Movement Disorder Society·Dietrich HaubenbergerRodger J Elble
Jun 15, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Fredricka C Martin, Adrian Handforth
Mar 10, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Kelly L SullivanTheresa A Zesiewicz
Sep 27, 2005·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Bassel Abou-Khalil
Mar 30, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Daniel TarsySusie I Ro
Jan 25, 2020·Current Neuropharmacology·Hortensia Alonso-NavarroFélix J Jiménez-Jiménez

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Neurology
Khalafalla O BusharaRupert E Exconde
Movement Disorders : Official Journal of the Movement Disorder Society
T A ZesiewiczK L Sullivan
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
D I GunalS Aktan
© 2021 Meta ULC. All rights reserved